Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study

NCT01517802 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT01517802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01517802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 3
Overall status
Completed
Start date
March 28, 2012
Completion date
April 22, 2021
Enrollment
32 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer, metastatic castration-resistant prostate cancer